drugset / Trial / NCT05983445

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

NCT05983445

Phase 3 Completed 313 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).

Timeline

Start
2023-01-11
Primary completion
2024-04-03
Completion
2024-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Genakumab Monoclonal antibody 200 mg Subcutaneous
Comparator betamethasone dipropionate Small molecule 7 mg Intramuscular

Indications